TickerFacts.

LENZ Therapeutics, Inc. (LENZ): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$287.0K
Year ended 2025-12-31
$453.0K
Trailing 12 months to 2026-06-30
2023-12-31: $15.0K2024-12-31: $58.0K2025-12-31: $287.0K$287.0K
2023-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$287.0K+394.8%2026-03-24, From 2025-01-01
2024-12-31$58.0K+286.7%2026-03-24, From 2024-01-01
2023-12-31$15.0Kn/a2025-03-19, From 2023-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
LENZ Therapeutics, Inc. (LENZ)2025-12-31$287.0K+394.8%
Alector, Inc. (ALEC)2025-12-31$5.72M+5.8%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$699.0K+19.1%
Scilex Holding Co (SCLX)2025-12-31$4.62M+14.3%
Caribou Biosciences, Inc. (CRBU)2025-12-31$3.65M-7.2%
Precision Biosciences Inc (DTIL)2025-12-31$1.47M-56.9%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$1.28M+60.4%
TScan Therapeutics, Inc. (TCRX)2025-12-31$2.90M-29.3%
Alpha Cognition Inc. (ACOG)2025-12-31$58.6K-27.9%

Compare LENZ, ALEC, LCTX, SCLX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗